Fesoterodine escalation to 8 mg after switch from first Overactive Bladder (OAB) therapy with Tolterodine ER is associated with additional patient-reported treatment benefit in daily practice: Findings from the IMPACTA study

Sánchez-Ballester F1, Castro-Díaz D2, Miranda P3, Lizarraga I4, Arumi D5, Rejas J6

Abstract Category

Detrusor Overactivity

Abstract 357
Non Discussion Poster
Scientific Non Discussion Poster Session 31
1. Department of Urology, Hospital General Universitario, Valencia, Spain, 2. Department of Urology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 3. Department of Gynecology, Hospital de Fuenlabrada, Madrid, Spain, 4. Medical Department, Pfizer SLU, 5. Medical Department, Pfizer Inc., 6. HEOR Department, Pfizer SLU